USE OF HIGH-INTENSITY STATIN THERAPY POST-ACUTE CORONARY SYNDROME IN THE ONGOING ODYSSEY OUTCOMES TRIAL OF ALIROCUMAB, A PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MONOCLONAL ANTIBODY, VERSUS PLACEBO: INTERIM BASELINE DATA

Background: Despite intensive statin therapy after acute coronary syndromes (ACS), the risk for recurrent cardiovascular (CV) events remains high and related to low-density lipoprotein cholesterol (LDL-C) levels. The ODYSSEY OUTCOMES trial tests the hypothesis that alirocumab, a fully human